Its activation by either oncogenic PIK3CA mutations (catalytic subunit alpha of PI3K) or by loss-of-function mutations of its negative regulator, phosphatase and tensin homolog (PTEN) modulates immune responses contributing to a survival benefit of cancer cells [38]. This evidence concerns the gene PIK3CA and cancer.